Table 2 Clinical data and relative scores of immunohistochemistry results from the Human Protein Atlas database
From: HYAL3 as a potential novel marker of BLCA patient prognosis
Protein | Tissue | Histological type | Age | Sex | Location | Quantity | Intensity | Relative IHC score |
|---|---|---|---|---|---|---|---|---|
HYAL3 | Urothelial carcinoma | Urinary bladder | 89 | Male | membranous nuclear | > 75% | Moderate | 8 |
HYAL3 | Urothelial carcinoma | Urinary bladder | 89 | Male | Cytoplasmic/membranous nuclear | > 75% | Moderate | 7 |
HYAL3 | Urothelial carcinoma | Urinary bladder | 63 | Female | Cytoplasmic/membranous | 75–25% | Moderate | 6 |
HYAL3 | Urothelial carcinoma | Urinary bladder | 63 | Female | Cytoplasmic/membranous | 75–25% | Moderate | 6 |
HYAL3 | Normal tissue | Urinary bladder | 55 | Male | Nuclear | 75–25% | Weak | 2 |
HYAL3 | Normal tissue | Urinary bladder | 51 | Male | Nuclear | 75–25% | Weak | 0 |